Skip to main content

PrEP clinical trials at UCSD

4 in progress, 2 open to eligible people

Showing trials for
  • Onboarding Positives and PrEP Users to Engage Negatives (OPPEN): Peer-driven Education to Link YMSM of Color to PrEP

    open to eligible males ages 18-34

    Onboarding Positives and PrEP users to Engage Negatives (OPPEN) is an intervention to train young Latino and Black men who have sex with men (YMSM of color) living with HIV or using pre-exposure prophylaxis (PrEP) to promote PrEP use among HIV-negative YMSM of color in their social networks. This pilot randomized controlled trial will evaluate OPPEN's acceptability, feasibility, and preliminary effect on PrEP care engagement among YMSM of color.

    San Diego, California

  • Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

    open to eligible people ages 16 years and up

    The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

    San Diego, California and other locations

  • Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

    Sorry, in progress, not accepting new patients

    This study uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new Proteus Digital Health (PDH) technologies approved by the FDA, to collect information about patients taking their Pre-Exposure Prophylaxis (PrEP) medication for HIV prevention. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which gives healthcare providers information about when patients have taken their PrEP medication. The purpose of the study is to demonstrate that the DHFS is easy to use and acceptable to people taking PrEP; that patients will persist with its use; and that the system provides valid, accurate measures of adherence.

    San Diego, California and other locations

  • Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate Pre-Exposure Prophylaxis (PrEP) levels in transgender-identifying or gender non-binary individuals taking versus not taking gender affirming hormone therapy. Subjects who have previously taken F/TDF as PrEP will continue with a fixed dose combination of daily oral F/TAF substituting for F/TDF. Subjects will receive the iTAB text messaging adherence reminders to provide personalized, automated text messages to support and monitor adherence that will vary by participant choice until 12 weeks after switching medication. This study will enroll 60 individuals to take F/TAF as PrEP for 48 weeks.

    San Diego, California

Our lead scientists for PrEP research studies include .

Last updated: